A pharmacogenetic study of escitalopram in autism spectrum disorders / Thomas OWLEY in Autism Research, 3-1 (February 2010)  

Public ISBD [article]  inAutism Research > 3-1 (February 2010) . - p.1-7 Titre : A pharmacogenetic study of escitalopram in autism spectrum disorders Type de document : Texte imprimé et/ou numérique Auteurs : Thomas OWLEY, Auteur ; Edwin H. Jr COOK, Auteur ; Bennett L. LEVENTHAL, Auteur ; Camille W. BRUNE, Auteur ; Jeff SALT, Auteur ; Laura WALTON, Auteur ; Steve GUTER, Auteur ; Nelson AYUYAO, Auteur ; Robert D. GIBBONS, Auteur Année de publication : 2010 Article en page(s) : p.1-7 Langues : Anglais (eng) Mots-clés : autistic-disorder escitalopram pharmacogenetics open-label drug-treatment Index. décimale : PER Périodiques Résumé : Objective: To determine the effect of serotonin transporter polymorphism promoter region (5-HTTPLR) genotypic variation (low, intermediate, and high expression groups) on response to escitalopram treatment of children and adolescents with autism spectrum disorders (ASDs). Method: The study used a forced titration, open label design, with genotype blind until study completion. Participants were children and adolescents aged 4-17 years of age with a confirmed ASD (autistic disorder, Asperger's disorder, or pervasive developmental disorder, not otherwise specified). Results: There was an interaction between genotype group and time on the Aberrant Behavior Checklist (ABC) Irritability Subscale (primary outcome variable) (linear maximum marginal likelihood estimation=-4.84, Z=-2.89, SE=1.67, P=0.004). Examination of baseline to last visit revealed that a genotype grouping based on a previous study of platelet 5-HT uptake revealed less response in the genotype group that had S/S genotype for 5-HTTLPR and did not have a diplotype in intron 1 previously shown to be associated with increased platelet 5-HT uptake. Conclusion: This genotype-blind, prospective pharmacogenetic study found the group of subjects with associated with the lowest platelet 5-HT uptake from previous study had the smallest reduction in ABC-Irritability scores after open label treatment with escitalopram. Replication is necessary to confirm these findings. En ligne : http://dx.doi.org/10.1002/aur.109 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=993 [article] A pharmacogenetic study of escitalopram in autism spectrum disorders [Texte imprimé et/ou numérique] / Thomas OWLEY, Auteur ; Edwin H. Jr COOK, Auteur ; Bennett L. LEVENTHAL, Auteur ; Camille W. BRUNE, Auteur ; Jeff SALT, Auteur ; Laura WALTON, Auteur ; Steve GUTER, Auteur ; Nelson AYUYAO, Auteur ; Robert D. GIBBONS, Auteur . - 2010 . - p.1-7. Langues : Anglais (eng) in Autism Research > 3-1 (February 2010) . - p.1-7 Mots-clés : autistic-disorder escitalopram pharmacogenetics open-label drug-treatment Index. décimale : PER Périodiques Résumé : Objective: To determine the effect of serotonin transporter polymorphism promoter region (5-HTTPLR) genotypic variation (low, intermediate, and high expression groups) on response to escitalopram treatment of children and adolescents with autism spectrum disorders (ASDs). Method: The study used a forced titration, open label design, with genotype blind until study completion. Participants were children and adolescents aged 4-17 years of age with a confirmed ASD (autistic disorder, Asperger's disorder, or pervasive developmental disorder, not otherwise specified). Results: There was an interaction between genotype group and time on the Aberrant Behavior Checklist (ABC) Irritability Subscale (primary outcome variable) (linear maximum marginal likelihood estimation=-4.84, Z=-2.89, SE=1.67, P=0.004). Examination of baseline to last visit revealed that a genotype grouping based on a previous study of platelet 5-HT uptake revealed less response in the genotype group that had S/S genotype for 5-HTTLPR and did not have a diplotype in intron 1 previously shown to be associated with increased platelet 5-HT uptake. Conclusion: This genotype-blind, prospective pharmacogenetic study found the group of subjects with associated with the lowest platelet 5-HT uptake from previous study had the smallest reduction in ABC-Irritability scores after open label treatment with escitalopram. Replication is necessary to confirm these findings. En ligne : http://dx.doi.org/10.1002/aur.109 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=993

The SOFIA Study: Negative Multi-center Study of Low Dose Fluoxetine on Repetitive Behaviors in Children and Adolescents with Autistic Disorder / Paul HERSCU in Journal of Autism and Developmental Disorders, 50-9 (September 2020)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 50-9 (September 2020) . - p.3233-3244 Titre : The SOFIA Study: Negative Multi-center Study of Low Dose Fluoxetine on Repetitive Behaviors in Children and Adolescents with Autistic Disorder Type de document : Texte imprimé et/ou numérique Auteurs : Paul HERSCU, Auteur ; Benjamin L. HANDEN, Auteur ; L. Eugene ARNOLD, Auteur ; Michael F. SNAPE, Auteur ; Joel D. BREGMAN, Auteur ; Lawrence GINSBERG, Auteur ; Robert HENDREN, Auteur ; Alexander KOLEVZON, Auteur ; Raun MELMED, Auteur ; Mark MINTZ, Auteur ; Nancy MINSHEW, Auteur ; Linmarie SIKICH, Auteur ; Ashraf ATTALLA, Auteur ; Brian KING, Auteur ; Thomas OWLEY, Auteur ; Ann CHILDRESS, Auteur ; Harry CHUGANI, Auteur ; Jean FRAZIER, Auteur ; Charles CARTWRIGHT, Auteur ; Tanya MURPHY, Auteur Article en page(s) : p.3233-3244 Langues : Anglais (eng) Mots-clés : Autism spectrum disorder  Repetitive behavior  Selective seretonin reuptake inhibitor Index. décimale : PER Périodiques Résumé : Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) that reduces obsessive-compulsive symptoms. There is limited evidence supporting its efficacy for repetitive behaviors (RRBs) in autistic spectrum disorder (ASD). We conducted a randomized controlled trial (RCT) of fluoxetine in 158 individuals with ASD (5-17 years). Following 14 treatment weeks (mean dose 11.8 mg/day), no significant differences were noted on the Children's Yale-Brown Obsessive Compulsive Scale; the proportion of responders was similar (fluoxetine: 36%; placebo: 41%). There were similar rates of AEs (e.g., insomnia, diarrhea, vomiting); high rates of activation were reported in both groups (fluoxetine: 42%; placebo: 45%). Overly cautious dosing/duration may have prevented attainment of a therapeutic level. Results are consistent with other SSRI RCTs treating RRBs in ASD.Trial Registration: clinicaltrials.gov Identifier: NCT00515320. En ligne : http://dx.doi.org/10.1007/s10803-019-04120-y Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=430 [article] The SOFIA Study: Negative Multi-center Study of Low Dose Fluoxetine on Repetitive Behaviors in Children and Adolescents with Autistic Disorder [Texte imprimé et/ou numérique] / Paul HERSCU, Auteur ; Benjamin L. HANDEN, Auteur ; L. Eugene ARNOLD, Auteur ; Michael F. SNAPE, Auteur ; Joel D. BREGMAN, Auteur ; Lawrence GINSBERG, Auteur ; Robert HENDREN, Auteur ; Alexander KOLEVZON, Auteur ; Raun MELMED, Auteur ; Mark MINTZ, Auteur ; Nancy MINSHEW, Auteur ; Linmarie SIKICH, Auteur ; Ashraf ATTALLA, Auteur ; Brian KING, Auteur ; Thomas OWLEY, Auteur ; Ann CHILDRESS, Auteur ; Harry CHUGANI, Auteur ; Jean FRAZIER, Auteur ; Charles CARTWRIGHT, Auteur ; Tanya MURPHY, Auteur . - p.3233-3244. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 50-9 (September 2020) . - p.3233-3244 Mots-clés : Autism spectrum disorder  Repetitive behavior  Selective seretonin reuptake inhibitor Index. décimale : PER Périodiques Résumé : Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) that reduces obsessive-compulsive symptoms. There is limited evidence supporting its efficacy for repetitive behaviors (RRBs) in autistic spectrum disorder (ASD). We conducted a randomized controlled trial (RCT) of fluoxetine in 158 individuals with ASD (5-17 years). Following 14 treatment weeks (mean dose 11.8 mg/day), no significant differences were noted on the Children's Yale-Brown Obsessive Compulsive Scale; the proportion of responders was similar (fluoxetine: 36%; placebo: 41%). There were similar rates of AEs (e.g., insomnia, diarrhea, vomiting); high rates of activation were reported in both groups (fluoxetine: 42%; placebo: 45%). Overly cautious dosing/duration may have prevented attainment of a therapeutic level. Results are consistent with other SSRI RCTs treating RRBs in ASD.Trial Registration: clinicaltrials.gov Identifier: NCT00515320. En ligne : http://dx.doi.org/10.1007/s10803-019-04120-y Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=430

---

1 (1 - 2 / 2)